How does BLE's PS Ratio compare to its peers?

BLE is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (7.8x).

How does BLE's PS Ratio compare vs other companies in the DE Biotechs Industry?

BLE is good value based on its Price-To-Sales Ratio (1.4x) compared to the European Biotechs industry average (8x).

What is BLE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BLE is good value based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).

What is the Fair Price of BLE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

BLE (€0.33) is trading below our estimate of [[fair value]] (€8.35)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

bluebird bio (MUN:BLE) - Stock Price, News & Analysis

BLE Stock Overview

A biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. More details

BLE fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Trading at 96% below our estimate of its fair value

Revenue is forecast to grow 41.53% per year

Trading at good value compared to peers and industry

Risk Analysis

Shareholders have been substantially diluted in the past year

Has less than 1 year of cash runway

Negative shareholders equity

Highly volatile share price over the past 3 months compared to the German market

+ 2 more risks

bluebird bio, Inc. Competitors

2invest

XTRA:2INV

€63.2m

Heidelberg Pharma

XTRA:HPHA

€106.7m

Medigene

XTRA:MDG1

€20.6m

co.don

XTRA:CNW

€6.5m

Price History & Performance

Summary of all time highs, changes and price drops for bluebird bio
Historical stock prices
Current Share Price	US$0.33
52 Week High	US$4.75
52 Week Low	US$0.29
Beta	0.80
11 Month Change	-28.58%
3 Month Change	-41.05%
1 Year Change	n/a
33 Year Change	-96.37%
5 Year Change	n/a
Change since IPO	-97.98%

Recent updates

Shareholder Returns

	BLE	DE Biotechs	DE Market
7D	15.0%	0.8%	0.8%
1Y	n/a	-18.3%	8.6%

Return vs Industry: Insufficient data to determine how BLE performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how BLE performed against the German Market.

Price Volatility

Is BLE's price volatile compared to industry and market?
BLE volatility
BLE Average Weekly Movement	13.1%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: BLE's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: BLE's weekly volatility has decreased from 21% to 13% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1992	282	Andrew Obenshain	www.bluebirdbio.com

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company’s product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia.

bluebird bio, Inc. Fundamentals Summary

How do bluebird bio's earnings and revenue compare to its market cap?
BLE fundamental statistics
Market cap	€68.67m
Earnings (TTM)	-€279.50m
Revenue (TTM)	€50.70m

1.4x

P/S Ratio

-0.2x

P/E Ratio

Is BLE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BLE income statement (TTM)
Revenue	US$53.12m
Cost of Revenue	US$78.78m
Gross Profit	-US$25.66m
Other Expenses	US$267.16m
Earnings	-US$292.82m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.51
Gross Margin	-48.31%
Net Profit Margin	-551.25%
Debt/Equity Ratio	-1,394.4%

How did BLE perform over the long term?

See historical performance and comparison

BLE Stock Overview

Rewards

Risk Analysis

bluebird bio, Inc. Competitors

XTRA:2INV

€63.2m

XTRA:HPHA

€106.7m

XTRA:MDG1

€20.6m

XTRA:CNW

€6.5m

Price History & Performance

Recent News & Updates

New major risk - Negative shareholders equity

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

Recent updates

New major risk - Negative shareholders equity

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 41% undervalued after recent price drop

Bluebird Bio, Inc. Announces FDA Approval of LYFGENIA™? (Lovo-Ccel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Now 24% undervalued

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Insider selling

President recently sold €54k worth of stock

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022)

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022)

Less than half of directors are independent

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021)

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold €78k worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold €94k worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer